Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19...
Gespeichert in:
| Veröffentlicht in: | Transfusion and apheresis science 2020-10, Vol.59 (5), p.102875-102875, Article 102875 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102875 |
|---|---|
| container_issue | 5 |
| container_start_page | 102875 |
| container_title | Transfusion and apheresis science |
| container_volume | 59 |
| creator | Abolghasemi, Hassan Eshghi, Peyman Cheraghali, Abdol Majid Imani Fooladi, Abbas Ali Bolouki Moghaddam, Farzaneh Imanizadeh, Sina Moeini Maleki, Matin Ranjkesh, Mohammad Rezapour, Mohammad Bahramifar, Ali Einollahi, Behzad Hosseini, Mohammad Javad Jafari, Nematollah Joneidi Nikpouraghdam, Mohamad Sadri, Nariman Tazik, Mokhtar Sali, Shanaz Okati, Shamsi Askari, Elham Tabarsi, Payam Aslani, Jafar Sharifipour, Ehsan Jarahzadeh, Mohammad Hossein Khodakarim, Nastaran Salesi, Mahmood Jafari, Ramezan Shahverdi, Samira |
| description | Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy. |
| doi_str_mv | 10.1016/j.transci.2020.102875 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_webof</sourceid><recordid>TN_cdi_webofscience_primary_000594183900016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473050220301804</els_id><sourcerecordid>S1473050220301804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-10c77462e6192a1577abc89061f5d1c517ff8ace014f62b67f11392afa259c4c3</originalsourceid><addsrcrecordid>eNqNUV2LFDEQHMTD-_InKHmXWdPJTJLxQZHR04ODg-P0NWQziWaZSZYku7L_3gyzt-iTPnXTXVWdVFXVK8ArwMDeblY5Kp-0WxFM5hkRvH1WXYDgogYm6PPSN5zWuMXkvLpMaYMxcOjYi-qcEtY1uKEX1b4fnXdajchYW6o-oGCRDn6vRpO08RltR5UmhWyIKEej8jQPC6i__377qYYOOW-Nzi749A49mLQbc5r3Ck2ldbOGiUg_3Ul5NxyuqzOrxmReHutV9e3m82P_tb67_3Lbf7yrdUtprgFrzhtGDIOOKGg5V2stOszAtgPoFri1QmmDobGMrBm3ALQgrSJtpxtNr6r3i-52t57MML8lqlFuo5tUPMignPx7491P-SPsJaeMCAJFoF0EdAwpRWNPXMByDkJu5DEIOQchlyAK7_Wfh0-sJ-cLQCyAX2YdbKEbr80JhjFuuwYE7UoHrHdZzQb3Yedzob75f2pBf1jQpvi8dybKI2NwscQmh-D-8ZffHrC_lg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Abolghasemi, Hassan ; Eshghi, Peyman ; Cheraghali, Abdol Majid ; Imani Fooladi, Abbas Ali ; Bolouki Moghaddam, Farzaneh ; Imanizadeh, Sina ; Moeini Maleki, Matin ; Ranjkesh, Mohammad ; Rezapour, Mohammad ; Bahramifar, Ali ; Einollahi, Behzad ; Hosseini, Mohammad Javad ; Jafari, Nematollah Joneidi ; Nikpouraghdam, Mohamad ; Sadri, Nariman ; Tazik, Mokhtar ; Sali, Shanaz ; Okati, Shamsi ; Askari, Elham ; Tabarsi, Payam ; Aslani, Jafar ; Sharifipour, Ehsan ; Jarahzadeh, Mohammad Hossein ; Khodakarim, Nastaran ; Salesi, Mahmood ; Jafari, Ramezan ; Shahverdi, Samira</creator><creatorcontrib>Abolghasemi, Hassan ; Eshghi, Peyman ; Cheraghali, Abdol Majid ; Imani Fooladi, Abbas Ali ; Bolouki Moghaddam, Farzaneh ; Imanizadeh, Sina ; Moeini Maleki, Matin ; Ranjkesh, Mohammad ; Rezapour, Mohammad ; Bahramifar, Ali ; Einollahi, Behzad ; Hosseini, Mohammad Javad ; Jafari, Nematollah Joneidi ; Nikpouraghdam, Mohamad ; Sadri, Nariman ; Tazik, Mokhtar ; Sali, Shanaz ; Okati, Shamsi ; Askari, Elham ; Tabarsi, Payam ; Aslani, Jafar ; Sharifipour, Ehsan ; Jarahzadeh, Mohammad Hossein ; Khodakarim, Nastaran ; Salesi, Mahmood ; Jafari, Ramezan ; Shahverdi, Samira</creatorcontrib><description>Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>EISSN: 1473-0502</identifier><identifier>DOI: 10.1016/j.transci.2020.102875</identifier><identifier>PMID: 32694043</identifier><language>eng</language><publisher>OXFORD: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Clinical trial ; Convalescent plasma ; COVID-19 ; COVID-19 - immunology ; COVID-19 - therapy ; Female ; Hematology ; Hospital stay ; Humans ; Immunization, Passive - adverse effects ; Life Sciences & Biomedicine ; Male ; Middle Aged ; Mortality rate ; SARS-CoV-2 - immunology ; SARS-CoV-2 - physiology ; Science & Technology ; Treatment Outcome ; Young Adult</subject><ispartof>Transfusion and apheresis science, 2020-10, Vol.59 (5), p.102875-102875, Article 102875</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>100</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000594183900016</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c533t-10c77462e6192a1577abc89061f5d1c517ff8ace014f62b67f11392afa259c4c3</citedby><cites>FETCH-LOGICAL-c533t-10c77462e6192a1577abc89061f5d1c517ff8ace014f62b67f11392afa259c4c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transci.2020.102875$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,28253,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32694043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abolghasemi, Hassan</creatorcontrib><creatorcontrib>Eshghi, Peyman</creatorcontrib><creatorcontrib>Cheraghali, Abdol Majid</creatorcontrib><creatorcontrib>Imani Fooladi, Abbas Ali</creatorcontrib><creatorcontrib>Bolouki Moghaddam, Farzaneh</creatorcontrib><creatorcontrib>Imanizadeh, Sina</creatorcontrib><creatorcontrib>Moeini Maleki, Matin</creatorcontrib><creatorcontrib>Ranjkesh, Mohammad</creatorcontrib><creatorcontrib>Rezapour, Mohammad</creatorcontrib><creatorcontrib>Bahramifar, Ali</creatorcontrib><creatorcontrib>Einollahi, Behzad</creatorcontrib><creatorcontrib>Hosseini, Mohammad Javad</creatorcontrib><creatorcontrib>Jafari, Nematollah Joneidi</creatorcontrib><creatorcontrib>Nikpouraghdam, Mohamad</creatorcontrib><creatorcontrib>Sadri, Nariman</creatorcontrib><creatorcontrib>Tazik, Mokhtar</creatorcontrib><creatorcontrib>Sali, Shanaz</creatorcontrib><creatorcontrib>Okati, Shamsi</creatorcontrib><creatorcontrib>Askari, Elham</creatorcontrib><creatorcontrib>Tabarsi, Payam</creatorcontrib><creatorcontrib>Aslani, Jafar</creatorcontrib><creatorcontrib>Sharifipour, Ehsan</creatorcontrib><creatorcontrib>Jarahzadeh, Mohammad Hossein</creatorcontrib><creatorcontrib>Khodakarim, Nastaran</creatorcontrib><creatorcontrib>Salesi, Mahmood</creatorcontrib><creatorcontrib>Jafari, Ramezan</creatorcontrib><creatorcontrib>Shahverdi, Samira</creatorcontrib><title>Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study</title><title>Transfusion and apheresis science</title><addtitle>TRANSFUS APHER SCI</addtitle><addtitle>Transfus Apher Sci</addtitle><description>Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Clinical trial</subject><subject>Convalescent plasma</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - therapy</subject><subject>Female</subject><subject>Hematology</subject><subject>Hospital stay</subject><subject>Humans</subject><subject>Immunization, Passive - adverse effects</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality rate</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 - physiology</subject><subject>Science & Technology</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1473-0502</issn><issn>1878-1683</issn><issn>1473-0502</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNUV2LFDEQHMTD-_InKHmXWdPJTJLxQZHR04ODg-P0NWQziWaZSZYku7L_3gyzt-iTPnXTXVWdVFXVK8ArwMDeblY5Kp-0WxFM5hkRvH1WXYDgogYm6PPSN5zWuMXkvLpMaYMxcOjYi-qcEtY1uKEX1b4fnXdajchYW6o-oGCRDn6vRpO08RltR5UmhWyIKEej8jQPC6i__377qYYOOW-Nzi749A49mLQbc5r3Ck2ldbOGiUg_3Ul5NxyuqzOrxmReHutV9e3m82P_tb67_3Lbf7yrdUtprgFrzhtGDIOOKGg5V2stOszAtgPoFri1QmmDobGMrBm3ALQgrSJtpxtNr6r3i-52t57MML8lqlFuo5tUPMignPx7491P-SPsJaeMCAJFoF0EdAwpRWNPXMByDkJu5DEIOQchlyAK7_Wfh0-sJ-cLQCyAX2YdbKEbr80JhjFuuwYE7UoHrHdZzQb3Yedzob75f2pBf1jQpvi8dybKI2NwscQmh-D-8ZffHrC_lg</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Abolghasemi, Hassan</creator><creator>Eshghi, Peyman</creator><creator>Cheraghali, Abdol Majid</creator><creator>Imani Fooladi, Abbas Ali</creator><creator>Bolouki Moghaddam, Farzaneh</creator><creator>Imanizadeh, Sina</creator><creator>Moeini Maleki, Matin</creator><creator>Ranjkesh, Mohammad</creator><creator>Rezapour, Mohammad</creator><creator>Bahramifar, Ali</creator><creator>Einollahi, Behzad</creator><creator>Hosseini, Mohammad Javad</creator><creator>Jafari, Nematollah Joneidi</creator><creator>Nikpouraghdam, Mohamad</creator><creator>Sadri, Nariman</creator><creator>Tazik, Mokhtar</creator><creator>Sali, Shanaz</creator><creator>Okati, Shamsi</creator><creator>Askari, Elham</creator><creator>Tabarsi, Payam</creator><creator>Aslani, Jafar</creator><creator>Sharifipour, Ehsan</creator><creator>Jarahzadeh, Mohammad Hossein</creator><creator>Khodakarim, Nastaran</creator><creator>Salesi, Mahmood</creator><creator>Jafari, Ramezan</creator><creator>Shahverdi, Samira</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20201001</creationdate><title>Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study</title><author>Abolghasemi, Hassan ; Eshghi, Peyman ; Cheraghali, Abdol Majid ; Imani Fooladi, Abbas Ali ; Bolouki Moghaddam, Farzaneh ; Imanizadeh, Sina ; Moeini Maleki, Matin ; Ranjkesh, Mohammad ; Rezapour, Mohammad ; Bahramifar, Ali ; Einollahi, Behzad ; Hosseini, Mohammad Javad ; Jafari, Nematollah Joneidi ; Nikpouraghdam, Mohamad ; Sadri, Nariman ; Tazik, Mokhtar ; Sali, Shanaz ; Okati, Shamsi ; Askari, Elham ; Tabarsi, Payam ; Aslani, Jafar ; Sharifipour, Ehsan ; Jarahzadeh, Mohammad Hossein ; Khodakarim, Nastaran ; Salesi, Mahmood ; Jafari, Ramezan ; Shahverdi, Samira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-10c77462e6192a1577abc89061f5d1c517ff8ace014f62b67f11392afa259c4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Clinical trial</topic><topic>Convalescent plasma</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - therapy</topic><topic>Female</topic><topic>Hematology</topic><topic>Hospital stay</topic><topic>Humans</topic><topic>Immunization, Passive - adverse effects</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality rate</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 - physiology</topic><topic>Science & Technology</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abolghasemi, Hassan</creatorcontrib><creatorcontrib>Eshghi, Peyman</creatorcontrib><creatorcontrib>Cheraghali, Abdol Majid</creatorcontrib><creatorcontrib>Imani Fooladi, Abbas Ali</creatorcontrib><creatorcontrib>Bolouki Moghaddam, Farzaneh</creatorcontrib><creatorcontrib>Imanizadeh, Sina</creatorcontrib><creatorcontrib>Moeini Maleki, Matin</creatorcontrib><creatorcontrib>Ranjkesh, Mohammad</creatorcontrib><creatorcontrib>Rezapour, Mohammad</creatorcontrib><creatorcontrib>Bahramifar, Ali</creatorcontrib><creatorcontrib>Einollahi, Behzad</creatorcontrib><creatorcontrib>Hosseini, Mohammad Javad</creatorcontrib><creatorcontrib>Jafari, Nematollah Joneidi</creatorcontrib><creatorcontrib>Nikpouraghdam, Mohamad</creatorcontrib><creatorcontrib>Sadri, Nariman</creatorcontrib><creatorcontrib>Tazik, Mokhtar</creatorcontrib><creatorcontrib>Sali, Shanaz</creatorcontrib><creatorcontrib>Okati, Shamsi</creatorcontrib><creatorcontrib>Askari, Elham</creatorcontrib><creatorcontrib>Tabarsi, Payam</creatorcontrib><creatorcontrib>Aslani, Jafar</creatorcontrib><creatorcontrib>Sharifipour, Ehsan</creatorcontrib><creatorcontrib>Jarahzadeh, Mohammad Hossein</creatorcontrib><creatorcontrib>Khodakarim, Nastaran</creatorcontrib><creatorcontrib>Salesi, Mahmood</creatorcontrib><creatorcontrib>Jafari, Ramezan</creatorcontrib><creatorcontrib>Shahverdi, Samira</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abolghasemi, Hassan</au><au>Eshghi, Peyman</au><au>Cheraghali, Abdol Majid</au><au>Imani Fooladi, Abbas Ali</au><au>Bolouki Moghaddam, Farzaneh</au><au>Imanizadeh, Sina</au><au>Moeini Maleki, Matin</au><au>Ranjkesh, Mohammad</au><au>Rezapour, Mohammad</au><au>Bahramifar, Ali</au><au>Einollahi, Behzad</au><au>Hosseini, Mohammad Javad</au><au>Jafari, Nematollah Joneidi</au><au>Nikpouraghdam, Mohamad</au><au>Sadri, Nariman</au><au>Tazik, Mokhtar</au><au>Sali, Shanaz</au><au>Okati, Shamsi</au><au>Askari, Elham</au><au>Tabarsi, Payam</au><au>Aslani, Jafar</au><au>Sharifipour, Ehsan</au><au>Jarahzadeh, Mohammad Hossein</au><au>Khodakarim, Nastaran</au><au>Salesi, Mahmood</au><au>Jafari, Ramezan</au><au>Shahverdi, Samira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study</atitle><jtitle>Transfusion and apheresis science</jtitle><stitle>TRANSFUS APHER SCI</stitle><addtitle>Transfus Apher Sci</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>59</volume><issue>5</issue><spage>102875</spage><epage>102875</epage><pages>102875-102875</pages><artnum>102875</artnum><issn>1473-0502</issn><eissn>1878-1683</eissn><eissn>1473-0502</eissn><abstract>Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.</abstract><cop>OXFORD</cop><pub>Elsevier Ltd</pub><pmid>32694043</pmid><doi>10.1016/j.transci.2020.102875</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-0502 |
| ispartof | Transfusion and apheresis science, 2020-10, Vol.59 (5), p.102875-102875, Article 102875 |
| issn | 1473-0502 1878-1683 1473-0502 |
| language | eng |
| recordid | cdi_webofscience_primary_000594183900016 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Adult Aged Aged, 80 and over Clinical trial Convalescent plasma COVID-19 COVID-19 - immunology COVID-19 - therapy Female Hematology Hospital stay Humans Immunization, Passive - adverse effects Life Sciences & Biomedicine Male Middle Aged Mortality rate SARS-CoV-2 - immunology SARS-CoV-2 - physiology Science & Technology Treatment Outcome Young Adult |
| title | Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T04%3A44%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20efficacy%20of%20convalescent%20plasma%20for%20treatment%20of%20COVID-19%20infections:%20Results%20of%20a%20multicenter%20clinical%20study&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Abolghasemi,%20Hassan&rft.date=2020-10-01&rft.volume=59&rft.issue=5&rft.spage=102875&rft.epage=102875&rft.pages=102875-102875&rft.artnum=102875&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/j.transci.2020.102875&rft_dat=%3Celsevier_webof%3ES1473050220301804%3C/elsevier_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32694043&rft_els_id=S1473050220301804&rfr_iscdi=true |